SCHOTT Pharma KGaA (XTRA:1SXP) Reports Higher Sales And Lower Earnings, Is It Fully Valued?
SCHOTT Pharma KGaA (XTRA:1SXP) reported third quarter 2026 results that combined higher sales with weaker profitability, giving investors fresh numbers on revenue momentum and margin pressure as of June 30.
See our latest analysis for SCHOTT Pharma KGaA.
The latest earnings come against a backdrop of strong recent momentum in SCHOTT Pharma KGaA's share price, with a 90 day share price return of 36.55% and a year to date share price return of 54.55%, even though the 1 year total shareholder return is slightly negative at 1.13%.
If this mix of growth and profitability trade offs has your attention, it can be a useful time to look at other healthcare related opportunities and see what is moving through 133 healthcare AI stocks
Bulls point to SCHOTT Pharma KGaA's revenue growth and recent share price surge. Bears focus on margin pressure and a slightly negative 1 year return. Which side do current valuation signals lean toward next?
Most Popular Narrative: 11.3% Overvalued
The most followed narrative for SCHOTT Pharma KGaA points to a fair value of €20.43, which sits below the latest close at €22.75, setting up a valuation story built around modest growth and margin assumptions.
Analysts are assuming SCHOTT Pharma KGaA's revenue will grow by 6.6% annually over the next 3 years. Analysts assume that profit margins will increase from 14.4% today to 15.8% in 3 years time.
Want to see why this narrative still points to an 11.3% premium to fair value? The crux lies in steady revenue expansion, firmer margins and a future earnings multiple that has to compress from today’s level. The full storyline connects these moving parts into one number.
Result: Fair Value of €20.43 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, SCHOTT Pharma KGaA still faces risks such as ongoing heavy capital expenditure and uncertain polymer syringe demand, which could challenge this overvaluation narrative.
Find out about the key risks to this SCHOTT Pharma KGaA narrative.
Another View On SCHOTT Pharma KGaA Using Earnings Multiples
While the narrative points to SCHOTT Pharma KGaA trading about 11.3% above a fair value of €20.43, the current P/E of 25.2x tells a different story. It is lower than the Global Life Sciences average of 37.7x and only slightly above a fair ratio of 24.6x. This suggests a tighter margin between potential upside and downside. Which signal do you trust more when the market mood shifts?
For a closer look at how this earnings based view stacks up against other checks, including peers and the fair ratio, see the breakdown in See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Conflicted about whether the current mix of growth assumptions and margin pressure around SCHOTT Pharma KGaA feels too optimistic or too cautious? Take a moment to review the key upside signals and weigh them against the risks through 2 key rewards
Looking for more investment ideas beyond SCHOTT Pharma KGaA?
If SCHOTT Pharma KGaA has sharpened your focus, do not stop with a single stock. Cast a wider net now so you do not miss opportunities quietly building elsewhere.
- Target resilient cash generators by reviewing companies in the 278 high quality undervalued stocks that combine quality fundamentals with prices that may not fully reflect their strengths.
- Strengthen your portfolio’s foundation by scanning stocks in the solid balance sheet and fundamentals stocks screener (433 results) where financial resilience takes center stage.
- Get ahead of the crowd by searching the screener containing 611 high quality undiscovered gems before attention and capital shift toward these under followed opportunities.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com